Replies to post #584995 on NorthWest Biotherapeutics Inc (NWBO)

[DrHigh]

Wouldnt NWBO investors (and canceer patients) have been better off if this move was done years ago. the rampant dilution and toucan equity giveway has certainly been way more harmful than the best deal we could have fetched at DL IMO.

[VikingInvest]

Are you in favor of the entire platform being managed by one company or do you think there's more value in licensing to various companies who each will have exclusivity for certain cancer indications?

Either way, I have a hard time seeing a 'complete sale' of NWBO. I think they will be a royalty company and continue to develop Direct as the true value for Direct is presently hard to determine.

I agree that they are definitely not set up for the 'going at it alone' model, so will partner one way or the other with either one or multiple BP's.

JMHO

[flipper44]

I think that’s correct Thermo. And the closest analogy I can draw is NASA’s work moving to commercial enterprises. NASA was slow, but who would have done it? Thanks NASA. Thanks NWBO.

Welcome commercialization.

[Doc logic]

thermo,

Change in governance I expect won’t come cheap as all the groundwork has been put in place for rapid expansion. Based on what Linda has said, NWBO has planned to take care of GBM themselves to build value before any selling. Partnering as of now would be with other indications with L until noted otherwise by management and there is no way she just hands over Direct without a very heavy front end premium or high co-development percentage. Just too valuable of an asset with closed automated manufacturing already in place, ready to be replicated and just waiting for approval after a shortened trial due to massively obvious efficacy as a tissue agnostic treatment.
Personally speaking I like the idea of a big financial backer with technical expertise like Maverick_1 is talking about. This would elevate value and Charles River Labs is no rookie or slouch CDMO to work with in that direction either. There will also be no lack of talent willing to move from big pharma into a conglomerate of specialty groups working together to provide research and support services. Linda Powers already has some of the best connections worldwide to cutting edge research and a development unit is not hard to imagine under the auspices of someone like Roger Perlmutter or partnership with Regeneron. Lots of really good possibilities along with the more seamless but likely more dilutive buyout option at some point. Lots of fun things to think about. Best wishes.

[biosectinvestor]

I can’t imagine they have not had conversations to release value on some of these other directions, but I would guess that the value paid by BP go way up with an already approved product and a cash flow positive company. They have to decide how long they want to wait, or what deal or deals they can get when.

I agree they can’t do everything that is possible alone at the current time. That delays development overall and many will be long gone before the potential is realized if they hold on to it too tightly. On the other hand, I imagine they believe, and I think realistically, that it takes a very careful and patient team to develop this kind of technology and handing it off to BP that has numerous failed trials without too much thought, is probably not great. They probably want to be very careful on the handovers in terms of the partners.